Visanji Naomi P, Mollenhauer Brit, Beach Thomas G, Adler Charles H, Coffey Christopher S, Kopil Catherine M, Dave Kuldip D, Foroud Tatiana, Chahine Lana, Jennings Danna
Morton & Gloria Shulman Movement Disorders Centre & Edmund J Saffra program in Parkinson's disease, Toronto Western Hospital, 399 Bathurst Street, MCl 7, Toronto, Ontario, M5T 2S8, Canada.
Paracelsus-Elena-Klinik, Klinikstrasse 16, 34128 Kassel, Germany.
Biomark Med. 2017 Apr;11(4):359-368. doi: 10.2217/bmm-2016-0366. Epub 2017 Mar 29.
The search for a biomarker for Parkinson's disease (PD) has led to a surge in literature describing peripheral α-synuclein (aSyn) in both biofluids and biopsy/autopsy tissues. Despite encouraging results, attempts to capitalize on this promise have fallen woefully short. The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for PD. S4 will evaluate aSyn in multiple tissues and biofluids within the same subject and across the disease spectrum to identify the optimal biomarker source and provide vital information on the evolution of peripheral aSyn throughout the disease. Additionally, S4 will correlate the systemic aSyn profile with an objective measure of nigrostriatal dopaminergic function furthering our understanding of the pathophysiological progression of PD.
对帕金森病（PD）生物标志物的探索导致了大量文献的涌现，这些文献描述了生物流体和活检/尸检组织中的外周α-突触核蛋白（aSyn）。尽管取得了令人鼓舞的结果，但利用这一前景的尝试却严重不足。系统突触核蛋白采样研究（S4）经过独特设计，旨在识别一种可重复的PD诊断和病情进展生物标志物。S4将在同一受试者体内的多种组织和生物流体中以及整个疾病谱中评估aSyn，以确定最佳生物标志物来源，并提供关于外周aSyn在整个疾病过程中演变的重要信息。此外，S4将把全身aSyn谱与黑质纹状体多巴胺能功能的客观测量结果相关联，从而加深我们对PD病理生理进展的理解。
